“India’s vaccine manufacturing capacity is incredible” says White House COVID-19 Response Coordinator

National & International News

Ashish Jha, White House COVID-19 Response Coordinator, praised India’s vaccine manufacturing capabilities during a White House press briefing on October 26. While describing India as a big supplier of vaccines, he described its vaccine manufacturing capacity as ‘amazing.’

Ashish Jha’s comment came in response to a question asking him about his view on India’s handling of the COVID crisis. Responding to the question, Jha said, “India because of its incredible manufacturing capacity, has been a major exporter of vaccines.” The questioner had also asked about the slowness in India and Quad cooperation, where India was supposed to manufacture the vaccines and Quad was to distribute them across the world.

Quad, also known as Quadrilateral Security Dialogue is a strategic security dialogue between four countries namely, India, US, Australia, and Japan. The main aim of Quad is to support a free and open Indo-Pacific and build supply chains.

“I have not looked at this very closely. My understanding of why it has slowed a bit is because global demand for vaccines has slowed, because, again, we have produced a lot of vaccines,” said Jha.

“But I think that Quad partnership is really important, and certainly important to this administration. India is an important manufacturer of vaccines for the world, not just for India itself. It’s a really important thing,” he added.

Earlier in February, the Ambassador of India to the United States, Taranjit Singh Sandhu had said that the cutting-edge technology and research leadership of the US and the capabilities of India, the world’s largest vaccine manufacturer, can be combined for producing affordable vaccines.

He emphasized that vaccinating the world must be the priority strategy against the pandemic adding that the world’s map of vaccinations presents a story of disparities with the under-developed countries including those in Africa lagging at 10 per cent or below.

The US International Development Finance Corporation and Biological E. Limited announced an expansion of Biological E.’s vaccine manufacturing plant in Hyderabad in October 2021 to support near-term COVID-19 response efforts. It will also boost long-term global health in India and the Indo-Pacific region, according to a news statement from the US Mission in India.

Also Read: New enzyme inhibitor offers hope for treatment of cancer

Follow Medically Speaking on Twitter Instagram Facebook